Raphael Weinberger1, Mark van der Linden2, Matthias Imöhl2, Rüdiger von Kries3. 1. Division of Epidemiology, Institute of Social Pediatrics and Adolescent Medicine, Ludwig-Maximilians-University Munich, Munich, Germany. Electronic address: Raphael.Weinberger@med.uni-muenchen.de. 2. National Reference Centre for Streptococci, Institute of Medical Microbiology, University Hospital RWTH Aachen, Aachen, Germany. 3. Division of Epidemiology, Institute of Social Pediatrics and Adolescent Medicine, Ludwig-Maximilians-University Munich, Munich, Germany.
Abstract
OBJECTIVE: To assess the vaccine effectiveness (VE) of PCV13 for invasive pneumococcal disease (IPD) regarding the extra six serotypes with a 3+1 schedule in Germany. METHODS: Active surveillance for IPD in children <16 years eligible for PCV13 vaccination. We used the Broome method and logistic regression to estimate VE. RESULTS: Data on 164/304 reported IPD cases were informative and met the inclusion criteria. VE for the extra six serotypes was 88% [95% confidence interval (CI): 73; 95] and 83% [56; 94] for at least one and for at least two doses respectively. VE for the complete 3+1 vaccination schedule was not conclusive because of a wide 95% CI. For serotype 3 VE appeared to be zero with an even wider 95% CI. CONCLUSION: PCV13 VE against the extra six serotypes with the 3+1 schedule in Germany was only marginally higher compared to previously published data for the 2+1 schedule.
OBJECTIVE: To assess the vaccine effectiveness (VE) of PCV13 for invasive pneumococcal disease (IPD) regarding the extra six serotypes with a 3+1 schedule in Germany. METHODS: Active surveillance for IPD in children <16 years eligible for PCV13 vaccination. We used the Broome method and logistic regression to estimate VE. RESULTS: Data on 164/304 reported IPD cases were informative and met the inclusion criteria. VE for the extra six serotypes was 88% [95% confidence interval (CI): 73; 95] and 83% [56; 94] for at least one and for at least two doses respectively. VE for the complete 3+1 vaccination schedule was not conclusive because of a wide 95% CI. For serotype 3 VE appeared to be zero with an even wider 95% CI. CONCLUSION: PCV13 VE against the extra six serotypes with the 3+1 schedule in Germany was only marginally higher compared to previously published data for the 2+1 schedule.
Authors: Tolulope A Adebanjo; Tracy Pondo; David Yankey; Holly A Hill; Ryan Gierke; Mirasol Apostol; Meghan Barnes; Susan Petit; Monica Farley; Lee H Harrison; Corinne Holtzman; Joan Baumbach; Nancy Bennett; Suzanne McGuire; Ann Thomas; William Schaffner; Bernard Beall; Cynthia G Whitney; Tamara Pilishvili Journal: Pediatrics Date: 2020-02-13 Impact factor: 7.124
Authors: Rotem Lapidot; Kimberly M Shea; Inci Yildirim; Howard J Cabral; Stephen I Pelton; The Massachusetts Department Of Public Health Journal: Pathogens Date: 2020-05-21
Authors: Lijoy Varghese; Louise Talbot; Andrea Govender; Xu-Hao Zhang; Bruce A Mungall Journal: Appl Health Econ Health Policy Date: 2018-06 Impact factor: 2.561
Authors: Heather L Sings; Philippe De Wals; Bradford D Gessner; Raul Isturiz; Craig Laferriere; John M McLaughlin; Stephen Pelton; Heinz-Josef Schmitt; Jose A Suaya; Luis Jodar Journal: Clin Infect Dis Date: 2019-05-30 Impact factor: 9.079